A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

BACKGROUND: Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does not significantly improve overall survival when compared to the sequential use of cytotoxic agents (CAIRO, MRC Focus, FFCD 2000-05). The present study investigates t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Giessen, Clemens, von Weikersthal, Ludwig Fischer, Hinke, Axel, Stintzing, Sebastian, Kullmann, Frank, Vehling-Kaiser, Ursula, Mayerle, Julia, Bangerter, Markus, Denzlinger, Claudio, Sieber, Markus, Teschendorf, Christian, Freiberg-Richter, Jens, Schulz, Christoph, Modest, Dominik Paul, Moosmann, Nicolas, Aubele, Philipp, Heinemann, Volker
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3173448/
https://ncbi.nlm.nih.gov/pubmed/21861888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-367
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados